Keith Chappell on a bivalent recombinant vaccine for COVID-19

Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Om Podcasten

Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.